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Our previous studies indicate that immunostimulatory DNA-based injectable hydrogels 
harboring unmethylated cytosine-phosphate-guanine (CpG) dinucleotides meet the 
requirements of an effective antigen delivery system, including safety, biodegradability, ease 
of administration, and stimulation of the innate immune system. However, rapid release of the 
model antigen ovalbumin (OVA) from the hydrogel limits its potential. Here it is aimed to 
achieve sustained OVA release from a DNA hydrogel through cationization of the antigen. 
Ethylenediamine (ED)-conjugated cationized OVA (ED-OVA), but not OVA, forms a 
complex with hexapod-like structured DNA, a component of the DNA hydrogel. The release 
of ED-OVA from the hydrogel is significantly slower than that of OVA. ED-OVA mixed with 
CpG DNA hydrogel efficiently binds to mouse dendritic DC2.4 cells and results in high 
antigen presentation. Intratumoral injections of ED-OVA/CpG DNA hydrogel significantly 
delays tumor growth of OVA-expressing EG7-OVA cells in mice.  Then, a cationic OVA 
peptide antigen (R8-L2-pepI) consisting of an OVA MHC class I epitope, octaarginine, and a 
linker is designed. Intratumoral injections of R8-L2-pepI/CpG DNA hydrogel eradicate 
tumors in 5 out of 6 mice. Thus, it is concluded that a vaccine consisting of 





The elimination of cancer cells by activation of the immune system is a general underlying 
mechanism of not only cancer immunotherapy but also other modalities of cancer therapy, 
including radiotherapy and chemotherapy [1]. Vaccination with tumor-associated antigens 




preclinical and clinical settings [2]. Recent studies demonstrated that adjuvants stimulating 
innate immunity are required to elicit potent adaptive immunity [3]. In addition, antigen 
delivery systems should possess the ability to continuously deliver tumor antigens to antigen 
presenting cells (APCs) as well as stimulate innate immunity [3]. They are also required to be 
safe, simple, chemically synthesizable, biocompatible, and biodegradable [4]. Today, various 
antigen delivery systems based on synthetic hydrogels and nanoparticles are reported [5-7]. 
One of the most well studied adjuvants is DNA containing unmethylated cytosine- 
phosphate-guanine (CpG) dinucleotides (CpG DNA) [8-10], which is recognized by Toll-like 
receptor 9 (TLR9) expressed by mammalian immune cells [11]. CpG DNA induces the release 
of T helper type Ӏ cytokines from TLR9-positive cells. There are several classes of CpG 
DNAs, the linkages of which are partially or fully phosphorothioated [12, 13]. Therapeutic 
applications of CpG DNA in chronic viral infection and cancer have been tested [14]. In its 
application as an adjuvant for cancer immunotherapy, CpG DNAs are generally administered 
with tumor-associated antigens, but little attention has been paid to the pharmacokinetics of 
the adjuvants. In addition, phosphorothioated DNA increases non-specific binding to proteins, 
which could lead to nephrotoxicity [15]. Therefore, enzymatically stable forms of 
phosphodiester CpG DNA can be an alternative to phosphorothioate modification as safer 
CpG DNA adjuvants [16, 17]. 
 Our studies on polypod-like structured DNA, or polypodna, which is a DNA 
assembly consisting of three or more oligodeoxynucleotides (ODNs), showed that such 
complicated structured DNAs serve as highly efficient delivery systems of CpG DNA to 
TLR9-positive immune cells [18-20]. Recently, we developed a ligase-free procedure for 
preparing DNA hydrogel, and found that this ligase-free DNA hydrogel is an injectable 




hydrogel and OVA [21]. We demonstrated that the CpG DNA-containing DNA hydrogel (CpG 
DNA hydrogel) encapsulating OVA was effective in inducing potent OVA-specific immune 
responses with less toxicity than complete Freund's adjuvant (CFA) or alum, a clinically 
available vaccine adjuvant [21]. However, OVA was released from the hydrogel with a half-life 
of about 2.5 h, and this rapid release reduced the potency of the injectable CpG DNA 
hydrogel as a controlled antigen delivery system with adjuvant activity. 
 Sustained release of antigen would increase antigen-specific immune responses [22]. 
Negatively charged OVA (isoelectric point of 4.5-4.8) hardly interacts with DNA, but its 
cationized derivatives would electrostatically interact. Based on these considerations, we 
aimed to achieve controlled release of the OVA antigen from DNA hydrogel by using 
positively charged antigens. Here we show that cationized OVA is slowly released from CpG 
DNA hydrogel, and intratumoral injections of this formulation is more potent than non-
cationized OVA/DNA hydrogel in suppressing the growth of EG7-OVA tumors in mice. 
Considering that antigen peptides have advantages over cationized antigen proteins in terms 
of product quality, purity, and productivity, we have also designed a cationic OVA peptide 
antigen (R8-L2-pepI) and demonstrated that injections of R8-L2-pepI/DNA hydrogel 
efficiently eradicated EG7-OVA tumors. 
 
2. Results 






Table 1. Characteristic of ED-OVA derivatives. OVA was modified with ED using EDAC. 
The degree of cationization was assessed by estimating the additional amino groups as 
measured by TNBS.  
 
 












OVA —— —— —— 0 -5.0 
ED7-
OVA 
100 10.0 31.2 7.3 +9.6 
ED17-
OVA 
100 16.0 53.0 16.7 +28.4 
 
 
Table 1 summarizes the number of modified carboxyl groups and the net charge of 
ethylenediamine (ED)-conjugated OVAs (ED-OVAs). The average number of modified 
carboxyl groups was 7.3 and 16.7 for ED7-OVA and ED17-OVA, respectively. The net charge, 
estimated from the amino acid composition and the degree of modification, was positive for 
both ED-OVA derivatives. Covalently conjugated oligomers or aggregates of OVA, which 
could be formed through the covalent bonding among ED-OVA molecules, were scarcely 
found in the ED-OVA samples, as assessed by sodium dodecyl sulfate-polyacrylamide gel 





Figure 1. Properties of OVA 
and ED-OVAs mixed with 
hexapodna or incorporated into DNA 
hydrogel. (a) OVA, (b) ED7-OVA, or 
(c) ED17-OVA was incubated with 
hexapodna at different mixing ratios 
for 15 min at 37 °C. The mixture was 
then subjected to electrophoresis 
using a 6 % polyacrylamide gel at 
200 V for 20 min, and DNA was 
detected with ethidium bromide. The 
molar ratios of GpC hexapodna and 
OVA or ED-OVAs were 1:0 (lane 2), 1:0.1 (lane 3), 1:0.2 (lane 4), 1:0.4 (lane 5), 1:1 (lane 6), 
1:5 (lane 7), 1:10 (lane 8), 1:50 (lane 9), and 1:100 (lane 10). The 100 bp DNA ladder is 
shown in lane 1 (Watson, Tokyo, Japan). (d) FITC-OVA or FITC-ED-OVAs (10 µg) were 
incorporated into 100 µg of CpG DNA hydrogel, and the product was placed into the upper 
chamber of the Transwell (0.4 µm pore size) with the bottom chamber containing phosphate 
buffered saline (PBS), and incubated at 37°C. The fluorescence intensity of the solution in the 
bottom chamber was measured, and the percentages of OVA or ED-OVAs released were 
calculated and plotted against time. Results are expressed as the mean ± S.D. of four 
independent samples. Results are typical of three separate experiments with similar results. (e) 
The fluorescent images of the hydrogel in the upper chamber were photographed at the 




were incubated with 500 µg/ml FITC-OVA or FITC-ED-OVAs in the presence or absence of 
10 μg/ml CpG DNA hydrogel. The amounts of FITC-OVA or FITC-ED-OVAs associated 
with the cells were measured by flow cytometry. Results are expressed as mean ± S.D. of four 
independent samples. Results are typical of four separate experiments with similar results. 
*P<0.05 compared with the medium group. (g) DC2.4 cells were plated on 96-well culture 
plates at a density of 5×104 cells/well and incubated overnight. DNA (10 μg/ml) and OVA or 
ED-OVAs (500 μg/ml) were added to each well, and then 5×104 CD8OVA1.3 cells were 
added and incubated at 37°C in 5% CO2 for an additional 24 h. The IL-2 concentration in 
culture media was measured by ELISA. Results are expressed as mean ± S.D. of four 
independent samples. Results are typical of four separate experiments with similar results. 
*P<0.05 compared with the medium group.  
 
Two sets of hexapod-like structured DNA (hexapodna) containing CpG DNA were 
designed, and an injectable DNA hydrogel was prepared by mixing as reported [21]. GpC DNA 
hydrogel was prepared by replacing CpG sequences in the ODNs of the CpG DNA hydrogel 
with GpC sequences, and was used as a control. Complex formation of OVA or ED-OVAs 
with DNA was examined by PAGE. Hexapodna containing GpC dinucleotide (GpC 
hexapodna-1) was used as model DNA. The migration of GpC hexapodna-1 slowed with 
increased addition of ED7-OVA or ED17-OVA (Figure 1a-c). By contrast, the addition of 
OVA had little impact on the migration of GpC hexapodna-1. Mixing ED-OVAs with GpC 
hexapodna-1 increased the apparent size of the samples, as measured by the dynamic light 




size of OVA and ED-OVAs, which indicates that aggregates were hardly formed in the 
cationization reaction.  
Figure 1d shows a time course of the fluorescence intensity of the bottom chamber of the 
Transwell plate after addition of CpG DNA hydrogel containing fluorescein isothiocyanate 
(FITC)-labeled OVA, FITC-ED7-OVA or FITC-ED17-OVA onto the insert. FITC-OVA was 
released from the DNA hydrogel with a half-life of less than 1 h, whereas the release of FITC-
ED-OVAs was much slower; with FITC-ED17-OVA demonstrating the slowest release rate. 
The slow release of FITC-ED-OVAs from the DNA hydrogel compared with FITC-OVA was 
confirmed by fluorescent images (Figure 1e). The released samples were collected 3 h after 
incubation and PAGE analysis was performed to detect the OVA protein as well as DNA 
(Figure S3a - c). The bands of OVA and ED-OVAs were smear because the gel was run 
under non-reducing conditions. Segments of OVA and DNA migrated to the same position in 
the polyacrylamide gel, suggesting that ED-OVAs are released in the complex form with 
DNA. The release of FITC-ED-OVAs from DNA hydrogel was accelerated in the presence of 
fetal bovine serum (FBS) (Figure S3d). The viscoelastic property of the DNA hydrogel was 
examined by measuring the storage modulus using a rheometer. No significant changes were 
observed in the storage modulus by the encapsulation of OVA or ED7-OVA into the hydrogel 
(Figure S4).  
 
2.2. Cellular uptake and MHC class Ӏ presentation of ED-OVA was increased by 
combination with DNA. 
Cellular uptake of FITC-OVA and FITC-ED-OVAs was examined in mouse dendritic DC2.4 




incubation with FITC-OVA or FITC-ED-OVAs in the presence or absence of CpG or GpC 
DNA hydrogel. The MFI of the cells treated with FITC-ED-OVAs was higher than that of 
cells treated with FITC-OVA, which could be due to the electrostatic interaction of ED-OVAs 
with the negatively charged cell surface. The addition of CpG DNA hydrogel significantly 
increased the cellular uptake of FITC-ED-OVAs, whereas only a slight increase was observed 
when the hydrogel was added to FITC-OVA. Similar results were obtained when the GpC 
DNA hydrogel was used instead of the CpG DNA hydrogel. 
MHC class I-restricted cross-presentation of OVA was measured using CD8OVA1.3 T 
hybridoma cells that release IL-2 upon stimulation with a complex of the SIINFEKL 
(OVA257-264) peptide and Kb (Figure 1g). Low IL-2 production was observed when 
CD8OVA1.3 T hybridoma cells interacted with OVA. In contrast, the addition of either ED7-
OVA or ED17-OVA resulted in higher amounts of IL-2 secretion. ED7-OVA was more potent 
than ED17-OVA in inducing IL-2 secretion, which correlates with our previous report [23]. 
Furthermore, addition of CpG or GpC DNA hydrogel to ED7-OVA significantly increased IL-
2 production. 
2.3. ED-OVA/CpG DNA hydrogel induced strong OVA-specific immune responses in 
mice. 
 As a result of its capacity to generate relatively higher IL-2 production upon interaction with 
CD8OVA1.3 T hybridoma cells, ED7-OVA was selected and used as the cationized OVA 
antigen in the following experiments. Figure 2a shows time course analyses of fluorescence 
intensity in mouse skin after intradermal injection of FITC-OVA or FITC-ED7-OVA at a dose 
of 10 μg in the presence or absence of CpG DNA hydrogel. The fluorescence intensity rapidly 




not significantly affected by co-injection with CpG DNA hydrogel. However, in mice 
receiving ED7-OVA, a slow decrease in fluorescence intensity was observed. Furthermore, 
the decrease was significantly delayed by the incorporation of FITC-ED7-OVA into CpG 
DNA hydrogel, which indicates that antigen release from DNA hydrogel is prolonged by use 
of cationized antigen. 
 
Figure 2. Disappearance of OVA or 
ED7-OVA from the injection site and 
induction of OVA-specific immune 
responses after intradermal injection of 
OVA or ED7-OVA into mice. (a) ICR 
mice were intradermally injected with 
10 μg FITC-OVA or FITC-ED7-OVA in 
the presence or absence of 100 μg CpG 
DNA hydrogel (10 μl/shot). At the 
indicated times after injection, mice 
were anesthetized and the skin tissues 
including the injection site were excised 
and homogenized. The fluorescence intensity of the supernatant of the homogenates was then 
measured. Results are expressed as mean ± S.D. of four mice. Results are typical of two 
separate experiments with similar results. *P<0.05 compared with the other groups. (b) 
C57BL/6 mice were immunized with OVA or ED7-OVA with or without DNA by three 
intradermal injections at weekly intervals. On day 7 post the last immunization, OVA-specific 




the dilution ratio at which the absorbance value of the saline group was obtained. Results are 
expressed as mean ± S.D. of four mice (saline-, CFA-, and OVA-treated groups) or five mice 
(other groups). Results are typical of two separate experiments with similar results. *P<0.05 
compared with the other groups. (c) On day 7 post the last immunization, splenocytes were 
collected, stimulated with OVA (1 mg/ml), and incubated for 4 days. The IFN-γ concentration 
in culture media was measured by ELISA. Results are expressed as mean ± S.D. of four mice 
(saline-, CFA-, and OVA-treated groups) or five mice (other groups). Results are typical of 
two separate experiments with similar results. *P<0.05 compared with the saline group. (d) 
TLR9 knockout mice were immunized with OVA or ED7-OVA with or without DNA by three 
intradermal injections at weekly intervals. On day 7 post the last immunization, splenocytes 
were collected, stimulated with OVA (1 mg/ml), and incubated for 4 days. The IFN-γ 
concentration in culture media was measured by ELISA. Results are expressed as mean ± S.D. 
of five mice. Results are typical of two separate experiments with similar results. *P<0.05 






Figure 3. Systemic and local adverse reactions after intradermal injection of OVA or ED7-
OVA into mice. (a) Spleens were collected from C57BL/6 mice on day seven after the third 
immunization at weekly intervals. Spleen weight was measured and large spleens indicated 
splenomegaly. Results are expressed as mean ± S.D. of five mice. *P<0.05 compared with the 
other groups. (b) Dermis length on day seven after the third immunization. (c) The number of 
leucocytes per length of dermis (number/mm). (d-l) Hematoxylin and eosin staining of the 
skin sections. (d) saline, (e) OVA/CFA, (f) OVA, (g) OVA/gel(GpC), (h) OVA/gel(CpG), (i) 






Figure 2b shows the OVA-specific total IgG antibody response in mice after immunization 
with OVA or ED7-OVA in the presence or absence of DNA hydrogel. Mice immunized with 
ED7-OVA showed higher IgG antibody levels than those immunized with OVA. 
Immunization of mice with ED7-OVA/CpG DNA hydrogel was more potent than 
immunization with ED7-OVA alone. GpC DNA hydrogel was less effective than CpG DNA 
hydrogel when co-injected with ED7-OVA. Figure 2c shows the IFN-γ production from 
splenocytes after re-stimulation with OVA, which is an indicator of the positive antigen 
specific responses. The ED7-OVA-treated group showed higher IFN-γ production than the 
OVA-treated group. The splenocytes of mice immunized with ED7-OVA/CpG DNA hydrogel 
produced higher amounts of IFN-γ than the cells immunized with ED7-OVA alone or 
OVA/CpG DNA hydrogel. In the case of TLR9 knockout mice, IFN-γ production was not 
increased by incorporation into CpG DNA hydrogel (Figure 2d). ED7-OVA mixed with CpG 
hexapodna (equimolar mixture of CpG hexapodna-1 and CpG hexapodna-3) was less 
effective than OVA incorporated into DNA hydrogel in inducing OVA-specific immune 
responses (Figure S5). The spleen weight of mice was significantly increased by 
immunization with OVA emulsified in CFA (Figure 3a), indicating this formulation 
developed splenomegaly, an undesirable adverse reaction of vaccination. No significant 
increase in spleen weight was observed in other groups, including the ED7-OVA/CpG DNA 
hydrogel-treated group. Infiltration of leucocytes at the injection site was also evaluated 
(Figure 3b-l). Despite comparable number of leukocytes being detected at the injection sites 
of ED7-OVA/CpG DNA hydrogel and OVA/CFA, the proportion of polymorphonuclear 




OVA/CpG DNA hydrogel-treated group than in the OVA/CFA-treated group. This suggests 
that ED7-OVA/CpG DNA hydrogel induced only slight acute inflammation, which was 
apparent in OVA/CFA-treated mice.  
 
2.4. Intratumoral injection of ED7-OVA/CpG DNA hydrogel delayed EG7-OVA tumor 







Figure 4. EG7-OVA tumor growth after intratumoral injection of ED7-OVA/CpG DNA 
hydrogel into mice. EG7-OVA cells (5×106 cells) were intradermally inoculated into 
C57BL/6 mice. (a and b) When tumor volumes reached >200 mm3, OVA or ED7-OVA (10 
µg) and DNA hydrogel (100 µg) were intratumorally injected three times at five-day intervals. 




S.E.M. of six mice (Gel (CpG)-, ED7-OVA-, and ED7-OVA/gel (GpC)-treated groups), seven 
mice (saline-, and OVA/gel (CpG)-treated groups) or eight mice (ED7-OVA/gel (CpG)-
treated group). Results are typical of two separate experiments with similar results. *P<0.05 
compared with the saline group.  (c-h) Tumor volume of individual animals treated with the 
following agents was plotted: (c) saline, (d) Gel (CpG), (e) OVA/gel(CpG), (f) ED7-OVA, (g) 
ED7-OVA/gel(GpC), (h) ED7-OVA/gel(CpG). Results are typical of two separate experiments 
with similar results. 
 
The anti-tumor effect of ED7-OVA/CpG DNA hydrogel was examined in EG7-OVA tumor-
bearing mice by intratumoral injection. Figure 4 shows the survival (a) and tumor size (b) of 
the tumor-bearing mice. ED7-OVA/CpG DNA hydrogel was the most potent treatment, 
significantly inhibiting the growth of EG7-OVA tumors and inducing complete tumor 
regression in 2 out of 8 mice (Figure 4c-h). OVA/CpG DNA hydrogel and ED7-OVA/GpC 
DNA hydrogel also delayed tumor growth but were much less effective than ED7-OVA/CpG 
DNA hydrogel. In order to examine the induction of antigen-specific immunity, the mice that 
rejected EG7-OVA tumor with ED7-OVA/CpG DNA hydrogel treatment were rechallenged 
with EG7-OVA cells and mouse melanoma B16-B16 cells 2 months after the first tumor 
inoculation. The mice rejected growth of EG7-OVA cells upon rechallenge, but did not reject 
B16-BL6 cells (Table S1), which indicates that antigens incorporated into CpG DNA 
hydrogel induce long term antigen specific immunity.  
2.5. Cationic antigen peptide encapsulated into CpG DNA hydrogel showed remarkable 






Figure 5. Complex formation of hexapodna and peptides and peptide release from DNA 
hydrogel. (a) pepӀ or (b) R8-L2-pepӀ was incubated with hexapodna at different mixing ratios 
for 15 min at 37°C. The mixture was subjected to electrophoresis using a 6% polyacrylamide 
gel at 200 V for 20 min and DNA was detected with ethidium bromide. The molar ratios of 
CpG hexapodna and pepӀ or R8-L2-pepӀ were 1:0 (lane 2), 1:0.1 (lane 3), 1:1 (lane 4), 1:10 
(lane 5), 1:50 (lane 6), 1:100 (lane 7). The 100 bp DNA ladder is shown in lane 1. (c) 0.1 
mg/ml pepӀ or R8-L2-pepӀ, and CpG hexapodna-1 was prepared using saline and mixed at 
various proportions. The size was then measured by DLS and expressed as the mean ± S.D. of 
twenty independent measurements. *P<0.05 compared with the other groups. (d) FITC-pepӀ 
(3.45 µg) or FITC-R8-L2-pepӀ (10 µg) was incorporated into 100 µg of CpG DNA hydrogel, 
and the product was placed into the upper chamber of the Transwell (0.4 µm pore size) with 
the bottom chamber containing PBS, and incubated at 37°C. The fluorescence intensity of the 




released were calculated and plotted against time. Results are expressed as the mean ± S.D. of 
four independent samples. Results are typical of two separate experiments with similar results. 
 
Peptide antigens are more frequently used in clinical practice and research than protein 
antigens. Therefore, the results obtained with ED-OVA were extended to a peptide antigen. 
The OVA MHC class Ӏ epitope, SIINFEKL (pepI), was selected as a model peptide antigen. 
Next, a cationic peptide antigen (R8-L2-pepI) was designed by linking octaarginine (R8) to 
the N-terminal of pepI through a FFRK linker (L2), which is reportedly cleaved by both 
lysosomal and non-lysosomal pathways [24]. The DNA band on PAGE analysis became 
weaker with increasing amounts of R8-L2-pepӀ (Figure 5a, b), indicating that R8-L2-pepI 
formed a complex with CpG hexapodna-1. The apparent size of the mixture of CpG 
hexapodna-1 and R8-L2-pepӀ was significantly larger than CpG hexapodna-1 alone (Fig. 5c). 
The release of FITC-R8-L2-pepӀ from CpG DNA hydrogel was much slower than that of 
FITC-pepI (Figure 5d). Intratumoral injections of R8-L2-pepӀ/CpG DNA hydrogel effectively 
increased the survival of tumor-bearing mice (Figure 6a) and inhibited the growth of EG7-
OVA tumors (Figure 6b). The EG7-OVA tumor completely regressed in 5 out of 6 mice 
treated with R8-L2-pepӀ/CpG DNA hydrogel (Figure 6c-i). Furthermore, mice that were 
treated with R8-L2-pepӀ/CpG DNA hydrogel rejected EG7-OVA cells, but not B16-BL6 cells 







Figure 6. EG7-OVA tumor growth after intratumoral injection of R8-L2-pepӀ/CpG DNA 
hydrogel into mice. EG7-OVA cells (5×106 cells) were intradermally inoculated into 
C57BL/6 mice. (a and b) When tumor volumes reached >200 mm3, pepӀ (3.45 µg) or R8-L2-
pepӀ (10 µg) and DNA hydrogel (100 µg) were intratumorally injected three times at five-day 
intervals. Survival (a) and tumor sizes (b) were measured every day. Results are expressed as 
mean ± S.E.M. of six mice. Results are typical of two separate experiments with similar 
results. *P<0.05 compared with the saline group. (c-h) Tumor volume of individual animals 




pepӀ/gel(GpC), (g) R8-L2-pepӀ, (h) R8-L2-pepӀ/gel(GpC), (i) R8-L2-pepӀ/gel(CpG). Results 
are typical of two separate experiments with similar results. 
 
3. Discussion 
Adjuvants are an essential component of vaccines used to efficiently elicit desirable immune 
responses [3]. Currently, insoluble aluminum salts, which were identified in the 1920s [25], are 
widely used in licensed vaccines [26]. However, due to safety concerns and the origin of the 
materials, there are very few licensed vaccine adjuvants that are approved for human use [4]. 
Generally, vaccine adjuvants need to be safe, simple, biodegradable, and synthetic for clinical 
application [26]. DNA hydrogel, which contains immunostimulatory CpG motifs, meets these 
requirements. One possible drawback of the injectable DNA hydrogel system that we 
developed could be the rapid release of antigens from the hydrogel [21]. In the present study, 
we however demonstrated that antigen release from DNA hydrogel can be prolonged by 
cationization of the antigen, and the combination of DNA hydrogel and cationized antigen 
efficiently induces antigen-specific tumor immunity. 
Drug release from hydrogels is mainly understood by diffusion-controlled mechanisms, 
and drug release rates are dependent on the diffusion coefficient [27]. Decreasing the diffusion 
coefficient leads to slow drug release from hydrogels. The diffusion coefficient is decreased 
by the reduction of mesh size or enhancement of the interaction between drugs and the gel 
matrix [28]. Concerning antigen release from negatively charged DNA hydrogel, the diffusion 
coefficient of antigens can be decreased by use of cationized antigens. DNA hydrogel will 
retain cationized antigens by electrostatic interaction, and the dissociation of the DNA 




the accelerated ED-OVA release from DNA hydrogel by DNase-containing FBS; DNase 
promotes the enzymatic degradation of the hydrogel, and this degradation then accelerates the 
release of ED-OVAs. This hypothesis is supported by the accelerated ED-OVA release from 
DNA hydrogel by DNase-containing FBS; DNase promotes the enzymatic degradation of the 
hydrogel, and this degradation then accelerates the release of ED-OVAs. The superior results 
of ED7-OVA/GpC DNA hydrogel over ED7-OVA alone (Figure 2b, c) indicate that the 
controlled release of OVA is important for the induction of OVA-specific immune responses, 
because GpC DNA hydrogel functions as a non-immunostimulatory, bioinert delivery system. 
Conversely, ED7-OVA mixed with CpG hexapodna was less effective than OVA/CpG DNA 
hydrogel in inducing OVA-specific immune responses (Figure S5), indicating the importance 
of controlled release of antigens for potent antitumor immunity. Taken together, these results 
indicate that both gradual release of antigen and the immune potentiating activity of CpG 
DNA hydrogel are important for the induction of antigen-specific tumor immunity (Figure 4, 
6). 
Previous studies demonstrated that cationized antigen proteins, ED-OVA and 
recombinant OVA containing polyarginine, could induce high levels of immune responses [23, 
29, 30]. In comparison to ED7-OVA, ED17-OVA with a higher degree of chemical modification, 
showed enhanced cellular uptake but inefficient antigen presentation (Figure 1f, g). This 
result was consistent with a previous report [23], and suggests that extensive modification 
interferes with epitope recognition. In this study, ED7-OVA/CpG DNA hydrogel showed 
superior therapeutic efficacy to OVA/CpG DNA hydrogel (Figure 4), although no significant 
differences were detected between these groups in the IgG antibody levels (Figure 2b). The 
differences that were detected between ED7-OVA/CpG DNA hydrogel and OVA/CpG DNA 




and the infiltration of leucocytes at the injection site (Figure 3c). Although the detailed 
mechanisms underlying the induction of antigen-specific immune responses after intratumoral 
injection remain to be elucidated, these differences observed could at least partly explain the 
higher activity of ED7-OVA/CpG DNA hydrogel in inhibiting tumor growth compared with 
OVA/CpG DNA hydrogel.  
It was also demonstrated that cationized OVA derivatives showed no significant local 
tissue damage in vivo [23]. In this study, the proportion of mononuclear leucocytes infiltrating 
the injection site was different between the ED7-OVA/CpG DNA hydrogel-treated and the 
OVA/CFA-treated groups (Figure 3c). One of the components of CFA is mineral oil, which is 
slowly cleared from injection sites [32]. However, DNA hydrogel disappears from the injection 
site with a half-life of about 12 h [21]. DNA is quickly degraded by nucleases under in vivo 
conditions, and this degradation would be involved in the clearance of DNA hydrogel, even 
though the hydrogel formation significantly retarded the disappearance of DNA from the 
injection site [21]. Therefore, ease of degradation could be related to the condition of 
inflammation at the injection site. This would be attributed to the characteristics of 
phosphodiester DNA used for the preparation of CpG DNA hydrogel. In contrast to 
phosphorothioate-stabilized CpG DNA, which is the compound used in most studies using 
CpG DNA [9, 33], phosphodiester DNA is susceptible to nuclease degradation. This enzymatic 
instability could explain the few adverse side effects induced by the CpG DNA hydrogel, 
even though it contained many CpG sequences (92.5 nmol per injection). No apparent 
splenomegaly in mice immunized with ED7-OVA/CpG DNA hydrogel (Figure 3a) indicates 
that no substantially harmful systemic immune reactions were induced by this formulation. 
We also reported that the concentration of IL-6 in serum hardly increased after intradermal 




Intratumoral injection was selected as the route of therapeutic immunization against 
EG7-OVA tumor-bearing mice. It is reported that direct injection of CpG ODN into tumors 
led to tumor regression by eliciting an antitumor T cell response [34, 35]. CpG ODN also 
inhibits the suppressive function of myeloid derived suppressor cells in tumor bearing hosts 
[36]. A phase 1/2 study demonstrated that in situ vaccination of skin lesions of cutaneous T-cell 
lymphoma patients with CpG ODN simultaneously with localized regional radiation is 
feasible, which suggests that intratumoral injection of CpG ODN can be safely performed [37]. 
Furthermore, intratumoral peptide injection enhanced tumor cell antigenicity [2]. Therefore, 
the antitumor effects observed with intratumorally injected cationized antigen/CpG DNA 
hydrogel is consistent with previous studies. 
Administration of R8-L2-pepӀ/CpG DNA hydrogel induced antigen specific tumor 
immunity more effectively than that of ED7-OVA/CpG DNA hydrogel (Figure 6). This could 
be due to the higher number of epitopes in R8-L2-pepӀ compared with ED7-OVA when 
administered at a dose of 10 µg/mouse. In addition, peptide based vaccines have superior 
properties to whole protein vaccines for several reasons. For example, peptides can be 
produced on a large scale by chemical synthesis without infectious materials, and quality 
control is possible through the use of techniques like liquid chromatography [38]. Furthermore, 
R8-L2-pepӀ and other cationic peptides can be obtained with high purity compared to 
chemically cationized antigen proteins, such as ED-OVAs. Thus, the use of peptides for 
cancer vaccination using cationized antigen could be an effective option for cancer therapy. 
 
4. Conclusion 
We have demonstrated that sustained release of antigen can be achieved through its 




induced antitumor immunity more effectively than unmodified antigen/DNA hydrogel. These 
findings have implications for optimal cancer immunotherapy based on CpG DNA hydrogel 
vaccination. 
 
5. Experimental Section  
Animals: Four-week-old ICR mice and six- to eight-week-old C57BL/6 mice were purchased 
from Japan SLC, Inc. (Shizuoka, Japan). TLR9 knockout (TLR9-/-) mice with a C57BL/6 
genetic background were purchased from Oriental Yeast Company (Tokyo, Japan). The 
protocols for animal experiments were approved by the Institutional Animal Experimentation 
Committee. 
Cell culture: Mouse dendritic DC2.4 cells were kindly provided by Dr. K. L. Rock 
(University of Massachusetts Medical School, Worcester, MA, USA). They were cultured in 
RPMI1640 (Nissui Co., Ltd., Tokyo, Japan) supplemented with 10% heat-inactivated FBS, 50 
μM monothioglycerol, antibiotics, L-glutamine, and non-essential amino acids (Life 
Technologies, Gibco®, USA). CD8OVA1.3, a mouse T cell hybridoma against an OVA class 
I epitope, was a generous gift from Dr. C. V. Harding (Case Western Reserve University, 
Cleveland, OH, USA). They were cultured in Dulbecco’s modified Eagle medium (DMEM; 
Nissui Pharmaceutical, Tokyo, Japan) supplemented with 10% heat-inactivated FBS, 50 μM 
monothioglycerol, antibiotics, and L-glutamine. EG7-OVA, an OVA transfectant of EL4, 
were purchased from American Type Culture Collection (Manassas, VA, USA). They were 
cultured in RPMI1640 supplemented with 10% heat-inactivated FBS, 50 μM 
monothioglycerol, antibiotics, and L-glutamine. Isolated mouse splenocytes were cultured in 
RPMI1640 supplemented with 10% heat-inactivated FBS, 50 μM monothioglycerol, 




Cancer Chemotherapy Center of the Japanese Foundation for Cancer Research, and cultured 
in DMEM supplemented with 10% heat-inactivated FBS, antibiotics, and L-glutamine. 
Cationization of OVA: OVA (albumin from chicken egg white, Sigma-Aldrich) was modified 
with ethylenediamine (ED, Wako Pure Chemical) using 1-(3-dimethylaminopropyl)-3-
carbodiimide (EDAC, Sigma-Aldrich) according to a previous report [39]. The degree of 
cationization was assessed by estimating the additional amino groups as measured by 
trinitrobenzenesulfonic acid (TNBS, Nacalai Tesque) [38]. The synthesis conditions and the 
physicochemical characteristics of OVA and ED-OVAs are summarized in Table 1. 
Peptide: OVA class Ӏ epitopes, pepӀ (SIINFEKL), and R8-L2-pepӀ 
(RRRRRRRRFFRKSIINFEKL), were purchased from GenScript (Piscataway, NJ, USA). The 
HPLC purity of pepӀ and R8-L2-pepӀ was 96.9% and 84.9%, respectively. Fluorescein 
isothiocyanate isomer 1 (FITC)-pepӀ and FITC-R8-L2pepӀ, in which FITC was conjugated at 
the N terminal of the peptides, were also obtained from GenScript. The HPLC purity of FITC-
pepӀ and FITC-R8-L2-pepӀ was 91.8% and 99.2%, respectively. 
Preparation of polypodna and DNA hydrogel: All phosphodiester ODNs were purchased from 
Integrated DNA Technologies, Inc. (Coralville, IA, USA). The sequences of the ODNs used 
are summarized in Table S3. Each hexapodna was prepared by mixing six equimolar ODNs as 
described previously [21]. DNA hydrogels were prepared by mixing equimolar amounts of two 
polypodna preparations in solution containing 150 mM sodium chloride. GpC DNA hydrogel, 
which was prepared by replacing CpG sequences in the ODNs for the CpG DNA hydrogel 
with GpC sequences, was used as a non-immunostimulatory DNA hydrogel.  
Complex formation of antigen with DNA: Antigen was incubated with GpC hexapodna-1 at 




subjected to electrophoresis using a 6% polyacrylamide gel at 200 V for 20 min, and DNA 
was subsequently detected with ethidium bromide.  
Release of antigen from DNA hydrogel: OVA and ED-OVAs were labeled with FITC (Sigma-
Aldrich) to obtain FITC-OVA and FITC-ED-OVAs, respectively. The FITC labeled antigens 
were added to hexapodna solutions and a CpG DNA hydrogel was prepared by mixing the 
solutions. Release of FITC labeled antigen from DNA hydrogel was then examined as 
previously reported [21]. 
Antigen presentation assay: DNA (10 μg/ml), OVA or ED-OVA (500 µg/ml), and 
CD8OVA1.3 cells were added to DC2.4 cells, the mixture was incubated for 24 h at 37°C, 
and antigen presentation was examined as previously reported [21]. 
Cellular uptake of antigen: DC2.4 cells (1×105 cells/well) on 48-well culture plates were 
incubated with DNA (10 μg/ml) and OVA or ED-OVAs (500 µg/ml) for 2 h at 37°C. The 
fluorescence intensity of the cells was then determined as previously reported [19]. 
Disappearance of antigen from the injection site: Under isoflurane induced anesthesia, ICR 
mice were intradermally injected with 10 μg of FITC-OVA or FITC-ED7-OVA in the 
presence or absence of 100 μg of DNA hydrogel (10 μl/shot). At the indicated times after 
injection, mice were anesthetized and skin tissues including the injection site were excised, 
and homogenized to collect supernatant. The fluorescence intensity of the supernatant of the 
homogenates was subsequently measured. 
Immunization of mice: Under isoflurane-induced anesthesia, C57BL/6 mice were injected 
with 10 μg OVA or ED7-OVA into the dorsal skin in the presence or absence of 100 μg DNA 




14. Seven days after the last immunization, mice were euthanized with isoflurane, and serum 
and spleen were collected. Serum samples were stored at -80°C until measurement.  
Measurement of OVA-specific antibody: Serum samples were serially diluted to measure the 
OVA-specific total IgG levels by ELISA as previously described [21]. 
IFN-γ secretion from spleen cells: Seven days after the last immunization, spleen cells were 
isolated, purified, and cultured in the presence of OVA (1 mg/ml) in 48-well culture plated for 
4 days. The concentration of IFN-γ in supernatant of the isolated spleen cells was measured as 
previously described [21].  
Measurement of spleen weight: Spleen was collected from different sets of C57BL/6 mice 
seven days after the third immunization at weekly intervals. Spleen weight was measured and 
large spleens were an indicator of splenomegaly, a systemic adverse effect of 
immunostimulatory compounds. 
Hematoxylin and eosin staining of skin sections: Under isoflurane induced anesthesia, the 
dorsal skin of C57BL/6 mice was injected with 10 μg OVA or ED7-OVA and 100 μg DNA or 
CFA. Mice were immunized three times on days 0, 7, and 14. Seven days after the last 
immunization, the injection site was excised, fixed in 4% paraformaldehyde, embedded in 
paraffin, sliced and stained with hematoxylin and eosin. Stained samples were examined 
under a microscope for histological evaluation. 
Treatment of tumor-bearing mice: C57BL/6 mice were inoculated intradermally with EG7-
OVA cells (5×106 cells/mouse). When the tumor volume exceeded 200 mm3, 100 μg of DNA 
and 10 μg of OVA, ED7-OVA, R8-L2-pepӀ, or 3.45 μg of pepӀ in a volume of 10 µl was 




intervals. The tumor size was measured with a slide caliper, and tumor volume was calculated 
using the following formula: tumor volume (mm3) = 0.5 × length (mm) × [width (mm)]2. 
Dynamic light scattering analysis: The apparent size of the antigen and hexapodna mixture 
was determined by the dynamic light scattering (DLS) method using a Malvern Zetasizer 
3000HS (Malvern Instruments, Malvern, UK) at 20°C.  
Statistical analysis: Statistical analyses were performed using Statcel3 (OMS Publishing, 
Saitama, Japan). Statistical differences were analyzed using one-way analysis of variance 
(ANOVA) followed by the Turkey-Kramer multiple comparison test. To analyze the 
antitumor effect, Kaplan-Meier survival curves were generated, and log-rank tests were 
performed. P values of < 0.05 were considered significant. 
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Immunostimulatory DNA hydrogel-based sustained release system using cationized 
antigen which can electrostatically interact with DNA is developed, and this system can 
induce antigen-specific immune responses, which leads to effective inhibition of antigen-
positive tumor growth in mice. This study provides experimental evidence for future clinical 
application of this system to induce potent antitumor immunity. 
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